


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:09Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407200" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407200</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>eid</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="brief-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Emerg Infect Dis</journal-id><journal-id journal-id-type="pmc-domain-id">782</journal-id><journal-id journal-id-type="pmc-domain">eid</journal-id><journal-id journal-id-type="publisher-id">EID</journal-id><journal-title-group><journal-title>Emerging Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1080-6040</issn><issn pub-type="epub">1080-6059</issn><publisher><publisher-name>Centers for Disease Control and Prevention</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407200</article-id><article-id pub-id-type="pmcid-ver">PMC12407200.1</article-id><article-id pub-id-type="pmcaid">12407200</article-id><article-id pub-id-type="pmcaiid">12407200</article-id><article-id pub-id-type="pmid">40867022</article-id><article-id pub-id-type="doi">10.3201/eid3109.250316</article-id><article-id pub-id-type="publisher-id">25-0316</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Dispatch</subject></subj-group><subj-group subj-group-type="article-type"><subject>Dispatch</subject></subj-group><subj-group subj-group-type="TOC-title"><subject>CYP2D6 Genotype and Primaquine Treatment in Patients with Malaria, Venezuela</subject></subj-group></article-categories><title-group><article-title>CYP2D6 Genotype and Primaquine Treatment in Patients with Malaria, Venezuela</article-title><alt-title alt-title-type="running-head">CYP2D6 Genotype in Patients with Malaria</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Pacheco</surname><given-names initials="C">C&#233;sar</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hern&#225;ndez-Acosta</surname><given-names initials="A">Ad&#225;n</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pulido</surname><given-names initials="N">Narviz</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ceballos</surname><given-names initials="Y">Yvanna</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saavedra</surname><given-names initials="D">Daniel</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>G&#243;mez</surname><given-names initials="C">Cruz</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moreno</surname><given-names initials="N">Nancy</given-names></name><xref rid="FN1" ref-type="fn">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Herrera</surname><given-names initials="F">Flor</given-names></name><xref rid="FN1" ref-type="fn">
<sup>1</sup>
</xref></contrib><aff>Centro de Investigaci&#243;n y de Estudios Avanzados del Instituto Polit&#233;cnico Nacional, Mexico City, Mexico (C. Pacheco); Instituto de Investigaci&#243;n en Ciencias de la Salud de la Secretar&#237;a de Marina, Pol&#237;gono Naval de San Pablo Tepetlapa, Mexico City (A. Hern&#225;ndez-Acosta); Universidad de Carabobo, Sede Aragua, Facultad de Ciencias de la Salud, Instituto de Investigaciones Biom&#233;dicas &#8220;Dr. Francisco J. Triana Alonso,&#8221; Estado Carabobo, Venezuela (N. Pulido, Y. Ceballos, D. Saavedra, N. Moreno, F. Herrera); FUNDASALUD Sucre, Direcci&#243;n Estadal de Salud Ambiental, Sucre, Venezuela (C. G&#243;mez)</aff></contrib-group><author-notes><corresp id="cor1">Address for correspondence: Flor Herrera, Universidad de Carabobo, Urb. San Pablo, Calle Hicelle, No 6, Turmero 2115, Venezuela; email: <email xlink:href="flormhq@gmail.com">flormhq@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><volume>31</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496169</issue-id><fpage>1807</fpage><lpage>1810</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="25-0316.pdf"/><abstract><p>We determined CYP2D6*4 and CYP2D6* genotypes and metabolizer phenotypes in 96 patients with suspected malaria in Venezuela and found intermediate or poor metabolizer phenotypes in &#8776;25% of cases. Nine of 44 malaria patients had <italic toggle="yes">Plasmodium vivax</italic> recurrence. Public health authorities should evaluate the benefits of increasing total doses of primaquine for treatment.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>malaria</kwd><kwd>Plasmodium vivax</kwd><kwd>vector-borne infections</kwd><kwd>parasites</kwd><kwd>CYP2D6 metabolizer phenotype</kwd><kwd>primaquine</kwd><kwd>Venezuela</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Malaria is prevalent in different tropical and subtropical regions, including those in Africa, Asia, and Latin America (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>). In Latin America, Brazil, Colombia, and Venezuela account for 76.8% of all reported cases. Most (72.1% in 2023) cases in that region are attributed to <italic toggle="yes">Plasmodium vivax</italic> (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>). Sucre State is a malaria-endemic region in Venezuela, where <italic toggle="yes">P. vivax</italic> is almost the only species (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>). Treatment of <italic toggle="yes">P. vivax</italic> malaria involves a combination therapy of chloroquine and primaquine, a prodrug that requires metabolic activation to elicit its antimalarial effect against hypnozoites (<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>).</p><p>Activation of primaquine is catalyzed by the metabolic enzyme cytochrome P450 2D6 (CYP2D6), which belongs to the CYP450 superfamily, a group of enzymes responsible for metabolism of many commonly prescribed drugs (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>). The <italic toggle="yes">CYP2D6</italic> gene is highly polymorphic and has &gt;150 different alleles (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>), encoding CYP2D6 isoforms with normal, decreased, increased, or no activity. In Venezuela, several CYP2D6 genotypes exhibiting the most prevalent null allele, <italic toggle="yes">CYP2D6</italic>*<italic toggle="yes">4</italic> (1846 G&gt;A, rs3892097), and the less frequent <italic toggle="yes">CYP2D6</italic>*<italic toggle="yes">6</italic> allele (1707delT, rs5030655) have been documented (<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref>,<xref rid="R6" ref-type="bibr"><italic toggle="yes">6</italic></xref>). For instance, the <italic toggle="yes">CYP2D6</italic>*<italic toggle="yes">4</italic> allele was observed at a frequency of 14% in an urban admixed population from Aragua, a nonmalaria state, and in Amerindian populations at frequencies of 4.2%&#8211;42.5% from Zulia (nonmalaria state) and 1.7%&#8211;5.45% from Bolivar (malaria state). The <italic toggle="yes">CYP2D6</italic>*<italic toggle="yes">6</italic> allele was observed at frequencies ranging from 0.3% to 1.2% in 2 urban admixed populations (<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref>,<xref rid="R6" ref-type="bibr"><italic toggle="yes">6</italic></xref>).</p><p>Malaria patients&#8217; response to primaquine treatment is contingent on the level of CYP2D6 activity. In cases where CYP2D6 activity is low, probability of treatment failure is higher (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>). Because CYP2D6 is necessary for primaquine metabolism, we determined the genotype of the most common <italic toggle="yes">CYP2D6</italic>*<italic toggle="yes">4</italic> variant and a less common <italic toggle="yes">CYP2D6</italic>*<italic toggle="yes">6</italic> variant with null activity and predicted the metabolizer phenotype in a sample of Mestizo persons with suspected <italic toggle="yes">P. vivax</italic> malaria from malaria-endemic Sucre state, Venezuela. We also evaluated the response to the standard treatment with primaquine.</p><sec sec-type="other1"><title>The Study</title><p>We conducted this study by using a sample of 96 patients (60 men and 36 women) exhibiting malaria symptoms. The patients were unrelated to each other and &gt;18 years of age. We recruited the patients in December 2022 from 4 health centers in the city of Cuman&#225;, municipality of Sucre, Sucre state, Venezuela (<xref rid="F1" ref-type="fig">Figure</xref>). We collected peripheral blood samples from the patients after they provided informed consent as approved by the Instituto de Investigaciones Biom&#233;dicas, Universidad de Carabobo Bioethics Committee (approval no. CBIIB-UC/2022-2).</p><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure</label><caption><p>Geographic area of Sucre municipality from a study of CYP2D6 genotype and primaquine treatment in malaria, Venezuela. Crosses represent health center locations in the Sucre municipality. Inset shows map of Venezuela with Sucre state in black.</p></caption><graphic position="float" orientation="portrait" xlink:href="25-0316-F.jpg"/></fig><p>We performed microscopic malaria diagnosis and validated positive results by using PCR (<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>). We extracted genomic DNA as previously described (<xref rid="R7" ref-type="bibr"><italic toggle="yes">7</italic></xref>) and conducted genotyping in accordance with previously outlined methods (<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref>). If we observed no nucleotide change in the 2 allelic variants analyzed, we designated the allele as <italic toggle="yes">CYP2D6</italic>*<italic toggle="yes">1</italic>. </p><p>We predicted metabolizer phenotype by using the activity score (AS) system (<xref rid="R8" ref-type="bibr"><italic toggle="yes">8</italic></xref>). In brief, we assigned values to the identified alleles ranging from 0 for no-function alleles (*<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>, *<xref rid="R6" ref-type="bibr"><italic toggle="yes">6</italic></xref>) to 2 for normal-function alleles (*<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>). The AS value of a given genotype is the sum of the assigned values for each allele. We designated patients with AS&#160;of&#160;0 as poor metabolizers, AS&#160;of&#160;1 as intermediate metabolizers, and AS&#160;of&#160;2 as normal metabolizers (<xref rid="R8" ref-type="bibr"><italic toggle="yes">8</italic></xref>,<xref rid="R9" ref-type="bibr"><italic toggle="yes">9</italic></xref>).</p><p>Among 96 participants, 44 (45.83%) were malaria positive. As expected, <italic toggle="yes">P. vivax</italic> malaria was predominant; 43 (97.72%) of the 44 malaria-positive patients were infected with <italic toggle="yes">P. vivax</italic>, and 1 (2.27%) was infected with <italic toggle="yes">P. falciparum</italic>. Of the 44 malaria-positive patients, 30 (68.18%) were men and 14 (31.81%) were women, which we anticipated: men have a higher malaria risk than women because their occupations are more likely to involve outdoor work, like fishing. The patients received standard oral primaquine treatment (0.25 mg/kg/d for 14 days) (<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>). On day 28, we evaluated patients for malaria recurrence, which was characterized by fever and parasitemia (<xref rid="R10" ref-type="bibr"><italic toggle="yes">10</italic></xref>).</p><p>We compared samples from the 52 malaria-negative participants and the 44 malaria-positive participants and found similar genotype profiles. CYP2D6*1*1 was the predominant genotype, which indicated a normal metabolizer phenotype. We saw a percentage of 75% in the 96 patients with the CYP2D6*1*1 genotype across both nonmalaria and malaria patients (<xref rid="T1" ref-type="table">Table</xref>). The other 25% of analyzed genotypes manifested as intermediate or poor metabolizer phenotypes, among which the CYP2D6*1*4 genotype showed the highest frequency and had an average of 17.75% across both groups. That frequency is substantially higher than the low frequency (2.37%) of that genotype identified within the population identified in Madagascar (<xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>). However, in 5 areas of Brazil, the CYP2D6*1*4 genotype exhibited a high frequency (35%&#8211;50%) (<xref rid="R12" ref-type="bibr"><italic toggle="yes">12</italic></xref>). That variation can be attributed to the different ethnic origins of the genotype, which differ across regions. The ancestors of the population of Madagascar are believed to be from Asia and Africa, whereas the ancestors of the highly heterogeneous populations from Venezuela and Brazil are thought to be from Spain and Portugal. In addition, the CYP2D6*4 genotype frequency within the group from Europe is high (<xref rid="R13" ref-type="bibr"><italic toggle="yes">13</italic></xref>). The metabolizer phenotype profile showed notable similarity across both groups; 75% of patients exhibited a normal metabolizer profile, 20.8% showed an intermediate metabolizer profile, and 4.19% displayed a poor metabolizer profile. Those values agree with values observed in ethnicity from Europe, thereby providing further substantiation for the initial assertion (<xref rid="R13" ref-type="bibr"><italic toggle="yes">13</italic></xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table</label><caption><title>Genotypes CYP2D6*4 and CYP2D6*6 and predicted phenotypes malaria and non malaria in patients with suspected malaria, Venezuela</title></caption><table frame="hsides" rules="groups"><col width="40" span="1"/><col width="54" span="1"/><col width="103" span="1"/><col width="139" span="1"/><col width="144" span="1"/><thead><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Genotype</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Activity score</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Predicted phenotype</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Nonmalaria patients, no. (%), n = 52</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Malaria patients, no. (%), n = 44</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1*1</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">Normal metabolizer</td><td valign="top" align="center" rowspan="1" colspan="1">39 (75)</td><td valign="top" align="center" rowspan="1" colspan="1">33 (75)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1*4</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">Intermediate metabolizer</td><td valign="top" align="center" rowspan="1" colspan="1">9 (17.31)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (18.19)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1*6</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">Intermediate metabolizer</td><td valign="top" align="center" rowspan="1" colspan="1">2 (3.85)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.27)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">4*4</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">Poor metabolizer</td><td valign="top" align="center" rowspan="1" colspan="1">1 (1.92)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.27)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">6*6</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">Poor metabolizer</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.27)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">6*4</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">Poor metabolizer</td><td valign="top" align="center" rowspan="1" colspan="1">1 (1.92)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap><p><italic toggle="yes">P. vivax</italic> recurrence was observed in 9 (20.5%) patients (6 men and 3 women); 7 exhibited an intermediate metabolizer phenotype, and 2 exhibited a poor metabolizer phenotype. That phenomenon might be attributed to a substantial correlation between the <italic toggle="yes">CYP2D6</italic> alleles with diminished activity, such as <italic toggle="yes">CYP2D6</italic>*<italic toggle="yes">4</italic> and *<italic toggle="yes">6</italic>, and the occurrence of primaquine therapeutic failure in patients infected with <italic toggle="yes">P. vivax</italic> (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>). High rates of relapses have already been reported in Venezuela (<xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>; J. Huber et al., unpub. data, <ext-link xlink:href="https://www.medrxiv.org/content/medrxiv/early/2022/05/12/2022.04.19.22274042.full.pdf" ext-link-type="uri">https://www.medrxiv.org/content/medrxiv/early/2022/05/12/2022.04.19.22274042.full</ext-link>). The recurrence of <italic toggle="yes">P. vivax</italic> shown in this study might be preventable by administering a higher dose (7.0 mg/kg) of primaquine instead of the conventional dose (3.5 mg/kg) (<xref rid="R10" ref-type="bibr"><italic toggle="yes">10</italic></xref>).</p><p>The first limitation of this study is the low number of patients; thus, our results might not be representative of all malaria-infected populations. Second, we only conducted patient monitoring on day 28 and thus only determined the clinical and parasitologic response and not the absence of <italic toggle="yes">P. vivax</italic> recurrence, which requires meticulous monitoring over a period of &#8776;6 months (<xref rid="R9" ref-type="bibr"><italic toggle="yes">9</italic></xref>); thus, we might have missed recurrence that occurred after 28 days.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>We estimated that &#8776;25% of malaria patients had nonfunctional alleles that would impair efficacy of primaquine. The corresponding predicted intermediate metabolizer phenotype was 20.8% and the poor metabolizer phenotype was 4.19% in a sample of malaria patients and nonmalaria patients susceptible to infection with <italic toggle="yes">P. vivax</italic> in Sucre, a malaria-endemic state of Venezuela. Those data are consistent with the 20.5% recurrence rate observed in <italic toggle="yes">P. vivax</italic> patients. To effectively treat malaria in the region, we recommend that public health authorities evaluate the potential benefits of increasing total doses of primaquine (7.0 mg/kg; 0.5 mg/kg/d) over a period of 14 days as an alternative to the current treatment regimen.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank all the patients who participated in the study; the staff of Ambulatorio La Llanada, Ambulatorio Cascajal, Hospital Julio Rodr&#237;guez, and Centro de Diagn&#243;stico Integral El Pe&#241;&#243;n of the state of Sucre, Venezuela, who provided technical assistance to the authors in the collection of samples; and Juan Ernesto Ludert for support in performing some of the experiments in his laboratory at Centro de Investigaci&#243;n y de Estudios Avanzados del Instituto Polit&#233;cnico Nacional. We used DeepL Write (<ext-link xlink:href="https://www.deepl.com/es/write" ext-link-type="uri">https://www.deepl.com/es/write</ext-link>) to enhance the quality of the writing style.</p><p>This work was supported by Instituto de Investigaciones Biom&#233;dicas, Universidad de Carabobo Venezuela.</p></ack><fn-group><fn fn-type="other"><p><italic toggle="yes">Suggested citation for this article</italic>: Pacheco C, Hern&#225;ndez-Acosta A, Pulido N, Ceballos Y, Saavedra D, G&#243;mez C, et al. CYP2D6 genotype and primaquine treatment in patients with suspected malaria, Venezuela. Emerg Infect Dis. 2025 Sep [<italic toggle="yes">date cited</italic>]. <ext-link xlink:href="https://doi.org/10.3201/eid3109.250316" ext-link-type="uri">https://doi.org/10.3201/eid3109.250316</ext-link></p></fn><fn id="FN1"><label>1</label><p>These authors were co&#8211;principal investigators.</p></fn></fn-group><bio id="d67e417"><p>Mr. Pacheco is a PhD student at Centro de Investigaci&#243;n y de Estudios Avanzados del Instituto Polit&#233;cnico Nacional. His research focuses on tropical infectious diseases and facilitating appropriate control solutions for policy makers.</p></bio><ref-list><title>References</title><ref id="R1"><label>1. </label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. World malaria report <year>2024</year> [<comment>cited 2025 Feb 8</comment>]. <ext-link xlink:href="https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024" ext-link-type="uri">https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024</ext-link></mixed-citation></ref><ref id="R2"><label>2. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wide</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pab&#243;n</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>De Abreu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bargues</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Salcedo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Capaldo</surname><given-names>J</given-names></string-name>, <etal>et al.</etal><article-title>Prevalence of asymptomatic <italic toggle="yes">Plasmodium vivax</italic> infections in the north-eastern focus of malaria of Venezuela.</article-title><source>Bol Mal Salud Amb.</source><year>2016</year>;<volume>56</volume>:<fpage>160</fpage>&#8211;<lpage>71</lpage>.</mixed-citation></ref><ref id="R3"><label>3. </label><mixed-citation publication-type="webpage"><collab>Centers for Disease Control and Prevention</collab>. Malaria diagnosis (United States). Treatment of uncomplicated malaria <year>2024</year> [<comment>cited 2025 Feb 10</comment>]. <ext-link xlink:href="https://www.cdc.gov/malaria/hcp/clinical-guidance/treatment-uncomplicated.html" ext-link-type="uri">https://www.cdc.gov/malaria/hcp/clinical-guidance/treatment-uncomplicated.html</ext-link></mixed-citation></ref><ref id="R4"><label>4. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Olvany</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Zimmerman</surname><given-names>PA</given-names></string-name>. <article-title>Global perspectives on <italic toggle="yes">CYP2D6</italic> associations with primaquine metabolism and <italic toggle="yes">Plasmodium vivax</italic> radical cure.</article-title><source>Front Pharmacol</source>. <year>2022</year>;<volume>13</volume>:<elocation-id>752314</elocation-id>. <pub-id pub-id-type="doi">10.3389/fphar.2022.752314</pub-id><pub-id pub-id-type="pmid">36457706</pub-id><pub-id pub-id-type="pmcid">PMC9705595</pub-id></mixed-citation></ref><ref id="R5"><label>5. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Flores-Angulo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Villegas</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mora</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mart&#237;nez</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Oropeza</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Moreno</surname><given-names>N</given-names></string-name>. <article-title>[Allelic variants of the CYP2D6: *4, *6 and *10 in a sample of resident from the Aragua state, Venezuela]</article-title><comment>[in Spanish]</comment>. <source>Rev Peru Med Exp Salud Publica</source>. <year>2015</year>;<volume>32</volume>:<fpage>746</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.17843/rpmesp.2015.324.1767</pub-id><pub-id pub-id-type="pmid">26732924</pub-id></mixed-citation></ref><ref id="R6"><label>6. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Griman</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Moran</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Valero</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Loreto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Borjas</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chiurillo</surname><given-names>MA</given-names></string-name>. <article-title>CYP2D6 gene variants in urban/admixed and Amerindian populations of Venezuela: pharmacogenetics and anthropological implications.</article-title><source>Ann Hum Biol</source>. <year>2012</year>;<volume>39</volume>:<fpage>137</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.3109/03014460.2012.656703</pub-id><pub-id pub-id-type="pmid">22324840</pub-id></mixed-citation></ref><ref id="R7"><label>7. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Rivero</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Urdaneta</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zoghbi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pernalete</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rubio-Palis</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Herrera</surname><given-names>F</given-names></string-name>. <article-title>Optimization of extraction procedure for mosquitos DNA suitable for PCR-based techniques.</article-title><source>Int J Trop Insect Sci</source>. <year>2004</year>;<volume>24</volume>:<fpage>266</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1079/IJT200430</pub-id></mixed-citation></ref><ref id="R8"><label>8. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gaedigk</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dinh</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Jeong</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Prasad</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Leeder</surname><given-names>JS</given-names></string-name>. <article-title>Ten years&#8217; experience with the CYP2D6 activity score: a perspective on future investigations to improve clinical predictions for precision therapeutics.</article-title><source>J Pers Med</source>. <year>2018</year>;<volume>8</volume>:<fpage>15</fpage>. <pub-id pub-id-type="doi">10.3390/jpm8020015</pub-id><pub-id pub-id-type="pmid">29673183</pub-id><pub-id pub-id-type="pmcid">PMC6023391</pub-id></mixed-citation></ref><ref id="R9"><label>9. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Nofziger</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Sangkuhl</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Whirl-Carrillo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ag&#250;ndez</surname><given-names>JAG</given-names></string-name>, <string-name name-style="western"><surname>Black</surname><given-names>JL</given-names></string-name>, <etal>et al.</etal><article-title>PharmVar GeneFocus: CYP2D6.</article-title><source>Clin Pharmacol Ther</source>. <year>2020</year>;<volume>107</volume>:<fpage>154</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1002/cpt.1643</pub-id><pub-id pub-id-type="pmid">31544239</pub-id><pub-id pub-id-type="pmcid">PMC6925641</pub-id></mixed-citation></ref><ref id="R10"><label>10. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chamma-Siqueira</surname><given-names>NN</given-names></string-name>, <string-name name-style="western"><surname>Negreiros</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Ballard</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Farias</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Silva</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Chenet</surname><given-names>SM</given-names></string-name>, <etal>et al.</etal><article-title>Higher-dose primaquine to prevent relapse of <italic toggle="yes">Plasmodium vivax</italic> malaria.</article-title><source>N Engl J Med</source>. <year>2022</year>;<volume>386</volume>:<fpage>1244</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2104226</pub-id><pub-id pub-id-type="pmid">35353962</pub-id><pub-id pub-id-type="pmcid">PMC9132489</pub-id></mixed-citation></ref><ref id="R11"><label>11. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mehlotra</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Gaedigk</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Howes</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Rakotomanga</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Ratsimbasoa</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Zimmerman</surname><given-names>PA</given-names></string-name>. <article-title><italic toggle="yes">CYP2D6</italic> genetic variation and its implication for <italic toggle="yes">vivax</italic> malaria treatment in Madagascar.</article-title><source>Front Pharmacol</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>654054</elocation-id>. <pub-id pub-id-type="doi">10.3389/fphar.2021.654054</pub-id><pub-id pub-id-type="pmid">33959023</pub-id><pub-id pub-id-type="pmcid">PMC8093859</pub-id></mixed-citation></ref><ref id="R12"><label>12. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Salles</surname><given-names>PF</given-names></string-name>, <string-name name-style="western"><surname>Perce-da-Silva</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Rossi</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Raposo</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Ramirez Ramirez</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Pereira Bastos</surname><given-names>OM</given-names></string-name>, <etal>et al.</etal><article-title><italic toggle="yes">CYP</italic>2D6 allele frequency in five malaria <italic toggle="yes">vivax</italic> endemic areas from Brazilian Amazon region.</article-title><source>Front Pharmacol</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>542342</elocation-id>. <pub-id pub-id-type="doi">10.3389/fphar.2021.542342</pub-id><pub-id pub-id-type="pmid">34366834</pub-id><pub-id pub-id-type="pmcid">PMC8343396</pub-id></mixed-citation></ref><ref id="R13"><label>13. </label><mixed-citation publication-type="book"><string-name name-style="western"><surname>Kane</surname><given-names>M</given-names></string-name>. CYP2D6 overview: allele and phenotype frequencies. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical genetics summaries. Bethesda (MD): National Center for Biotechnology Information; <year>2012</year>. p. 1&#8211;34.<pub-id pub-id-type="pmid">28520340</pub-id></mixed-citation></ref><ref id="R14"><label>14. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sojo-Milano</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>C&#225;ceres</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Pizzo</surname><given-names>NN</given-names></string-name>, <string-name name-style="western"><surname>Rojas</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Maldonado</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rubio-Pulgar</surname><given-names>N</given-names></string-name>, <etal>et al.</etal><article-title>Malaria recurrent <italic toggle="yes">Plasmodium vivax</italic>. Municipio Cajigal, Estado Sucre, Venezuela.</article-title><source>Rev Biomed.</source><year>2008</year>;<volume>19</volume>:<fpage>3</fpage>&#8211;<lpage>15</lpage>.</mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>